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BACKGROUND: Cyclooxygenase-2 (COX-2) is over-expressed in colorectal cancer (CRC), rendering tumour cells resistant to
apoptosis. Selective COX-2 inhibition is effective in CRC prevention, although having adverse cardiovascular effects, thus focus has
shifted to downstream pathways.
METHODS: Microarray experiments identified genes regulated by COX-2 in HCA7 CRC cells. In vitro and in vivo regulation of DRAK2
(DAP kinase-related apoptosis-inducing kinase 2 or STK17b, an apoptosis-inducing kinase) by COX-2 was validated by qRT-PCR.
RESULTS: Inhibition of COX-2 induced apoptosis and enhanced DRAK2 expression in HCA7 cells (4.4-fold increase at 4h by
qRT-PCR, P¼0.001), an effect prevented by co-administration of PGE2. DRAK2 levels were suppressed in a panel of human
colorectal tumours (n¼10) compared to normal mucosa, and showed inverse correlation with COX-2 expression (R¼ 0.68,
R
2¼0.46, P¼0.03). Administration of the selective COX-2 inhibitor rofecoxib to patients with CRC (n¼5) induced DRAK2
expression in tumours (2.5-fold increase, P¼0.01). In vitro silencing of DRAK2 by RNAi enhanced CRC cell survival following COX-2
inhibitor treatment.
CoNCLUSION: DRAK2 is a serine–threonine kinase implicated in the regulation of apoptosis and is negatively regulated by COX-2
in vitro and in vivo, suggesting a novel mechanism for the effect of COX-2 on cancer cell survival.
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Colorectal cancer (CRC) remains a leading cause of cancer
death, with worldwide one million new cases each year and as
many as half a million cancer deaths annually (Boyle and
Leon, 2002). Cyclooxygenase-2 (COX-2) expression is increased
in the majority of colorectal tumours (Eberhart et al, 1994) and
this induction is associated with advanced tumour stage and
correlates with poor clinical outcomes (Sheehan et al, 1999). Non-
steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX
activity, show anti-neoplastic effects in vitro (Richter et al, 2001;
Sheng et al, 1997) and human studies have demonstrated their use
to be associated with a reduced incidence of colorectal neoplasia
(Baron et al, 2003; Sandler et al, 2003). Although more recent
studies have confirmed the chemopreventive activity of COX-2-
selective NSAIDs (Arber et al, 2006; Baron et al, 2006; Bertagnolli
et al, 2006), it is also clear that their long-term use is associated
with an unacceptable increase in the risk of cardiovascular events
(Bertagnolli et al, 2006; Bresalier et al, 2005).
The anti-neoplastic properties of these agents result from the
inhibition of prostaglandin generation, particularly that of
prostaglandin E2 (PGE2), the most abundant in vivo product of
COX-2 activity in CRC cells (Pugh and Thomas, 1994; Rigas et al,
1993). Although it appears that PGE2 modulates various processes
that are fundamental to tumour cell survival, such as altered
proliferation and susceptibility to apoptosis (Sheng et al,
1997, 1998, 2001; Tang et al, 2002), the precise molecular
mechanisms remain unclear. A strong rationale exists therefore
to generate a more complete understanding of the downstream
targets of COX-2 activity (Doherty and Murray, 2009). This may
lead to the development of more refined therapies, with side-effect
profiles that allow their generalised use. Previous studies examin-
ing gene regulation by COX-2 in CRC cells have focused on long
time points and have used relatively high doses of NSAIDs (Zhang
and DuBois, 2001). With this in mind, we set out to explore early
changes in gene expression in CRC cells resulting from low-dose
treatment with a selective COX-2 inhibitor, to improve our
understanding of the early signalling events downstream of
prostaglandin production. One candidate gene that we have
identified, DRAK2 (DAP kinase-related apoptosis-inducing kinase
2 or STK17b), is one of a family of serine threonine kinases that
share the ability to induce apoptosis (Sanjo et al, 1998). The aim
of this study was to explore the relationship between COX-2
and DRAK2 as a potential downstream regulator of cell survival
in CRC. Received 6 March 2009; revised 18 May 2009; accepted 21 May 2009
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Cell culture
All cells were grown in culture at 371C in a humidified 5% CO2
incubator. HCA7 cells were kindly donated by Susan Kirkland
(ICRF, London, UK). HCA7 cells were cultured in DMEM with 10%
FBS, supplemented with 1mM sodium pyruvate and 100mgml
 1
kanamycin, to approximately 90% confluence before treatment.
HT29 cells were purchased from the ATCC (Rockville, MD, USA)
and maintained in McCoy’s 5A medium containing 1.5mM
L-glutamine, 10% FBS, penicillin 100Uml
 1 and streptomycin
100mgml
 1. SC236, a selective COX-2 inhibitor, was a gift from
Dr Peter Isakson (Searle, Skokie, IL, USA). PGE2 was purchased
from Cayman (St Louis, MO, USA). Staurosporine was purchased
from Calbiochem (San Diego, CA, USA). A validated siRNA against
a target sequence in exon 3 of the DRAK2 (STK17b) gene was
purchased from Ambion Inc (Austin, TX, USA). siRNA to
scrambled DRAK2 sequence target (scrambled/negative control)
was in vitro transcribed from oligonucleotide template using
Silencer siRNA construction kit (Ambion Inc) . pEGFP-N1 vector
was purchased from BD Clontech (San Jose, CA, USA).
High-density oligonucleotide arrays
Total RNA was isolated from cells and tissue following homogeni-
sation in RNA lysis buffer (Qiagen GmbH, Hilden, Germany)
supplemented with 1% b-mercaptoethanol. Extraction was performed
using RNeasy Midi kits (Qiagen GmbH). RNA quality was determined
by agarose gel analysis and RNA concentration was determined by
spectrophotometry (GeneQuant pro; Amersham Biotech, Bucks, UK).
Total RNA was isolated as outlined above from HCA7 cells
treated for 4, 6 and 8h with SC236 (5mM) or vehicle. cDNA was
synthesised using the Custom SuperScript ds-cDNA synthesis kit
(Invitrogen, Carlsbad, CA, USA). Samples from various time points
were pooled and underwent in vitro transcription using the ENZO
IVT kit (Affymetrix, Santa Clara, CA, USA) to form biotin-labelled
cRNA. This was fragmented and three independent biological
samples for both control and treated conditions were then
hybridised to Affymetrix U95Av2 GeneChips according to
Affymetrix protocols. A detailed description of microarray analysis
is included as Supplementary methods.
Quantitative RT-PCR
Total RNA (1mg) was reverse transcribed using Moloney murine
leukaemia virus reverse transcriptase (Promega, Madison,
WI, USA) according to the manufacturer’s instructions. DRAK2,
COX-2 and vascular endothelial growth factor (VEGF) were
quantified by RT–PCR using SYBR Green Universal Master Mix
(Roche Diagnostics Corp., Indianapolis, IN, USA). Reactions were
carried out in a 96-well format in the ABI 7700 Sequence Detector
(PerkinElmer/Applied Biosystems, Warrington, Cheshire, UK).
Results were then normalised to 18S rRNA amplified from the
same cDNA mix and expressed as fold induction compared with
the controls. cDNAs were amplified using the following primer
pairs: DRAK2, AAAATAGGGCATGCGTGTGAA and TATTATACC
AATATTCCACATATCTGTTGCT; COX-2, TTGTACCCGGACAGG
ATTCTATG and TGTTTGGAGTGGGTTTCAGAAATA; VEGF, CA
TGCAGATTATGCGGATCAA and TTTGTTGTGCTGTAGGAAGCT
CAT. Bax and Bcl-xl quantification was performed using TaqMan
pre-developed assay reagents according to the manufacturer’s
protocol (Applied Biosystems, Foster City, CA, USA).
Confocal microscopy
HCA7 cells were grown on glass chamber slides and treated with
SC236 (5mM) or vehicle control for 24h. Slides were air-dried, fixed
(methanol) and permeabilised (cold acetone). Slides were then
blocked with 1% BSA in PBS (2h) and incubated with a 1:50 dilution
of anti-DRAK2 antibody (Santa Cruz Biotech, Santa Cruz, CA,
U S A )o v e r n i g h ta t4 1C. After serial washes, the slides were incubated
with a 1:250 dilution of fluorescently labelled donkey anti-goat
Alexa Fluor 488 (Molecular Probes, Leiden, the Netherlands) and
subsequently propidium iodide (Molecular Probes) diluted at
1mgml
 1 in PBS as a nuclear counterstain for 5min. Slides were
mounted with fluorescent mounting media (Dako, Carpinteria,
CA, USA) and imaged with an LSM510 Zeiss Axioplan-2 upright
confocal microscope (Carl Zeiss, Go ¨ttingen, Germany).
FITC–Annexin V apoptosis assay
HCA7 cells were seeded at a density of 0.5 10
6 cells per well in
six-well plates and were treated with SC236 (5mM) or vehicle
control for 24h. Cells were detached using Versene for 5min at
371C and floating and adherent cells were then pelleted by
centrifugation and washed in a solution of 2% BSA suspended in
PBS. We performed FITC–Annexin V/propidium iodide labelling
was performed using a TACS Annexin V–FITC Apoptosis
detection kit (R&D Systems, Abingdon, UK). Briefly, cells were
re-suspended in a 100ml working stock of binding buffer,
propidium iodide and Annexin V–FITC conjugate and incubated
in the dark for 15min. Cells were re-suspended in binding buffer
before analysis in a FACScalibur flow cytometer (Becton
Dickinson, Oxford, UK) with measurement of fluorescence
emission at 530nm (FL1 channel) and at 4575nm (FL3 channel).
Four quadrant analyses using CellQuest (Becton Dickinson,
Oxford, UK) software allowed quantification of cell populations
according to labelling characteristics. The results were verified by
staining/morphology by confocal microscopy.
RNA interference and phenotypic characterisation
HT-29 cells were seeded at a density of 0.5 10
6 cells per well in
six-well plates and allowed to adhere overnight, then co-
transfected with 3mg of DRAK2 siRNA and 1mg of pEGFP-N1
(as a marker to select transfected cells) DNA per well using Fugene
6.0 (Roche Diagnostics Corp.) with a 2mg:1ml ratio of RNA to
transfection reagent. Transfections were performed in OptiMEM,
1ml per well (final concentration of siRNA, approximately
200nM). A negative control siRNA to a scrambled target in the
DRAK2 gene (without sequence homology to any other known
transcript as verified by BLAST analysis) was used in the mock
transfection controls. Populations of both mock- and positively
transfected cells were subsequently treated with either SC236
(5mM), staurosporine (1mM) or vehicle control for 24h. Adherent
and floating cells were then pelleted, washed and then
re-suspended in 250ml of PBS with 7-aminoactinomycin D
(7-ADD; Molecular Probes) at a final concentration of 20mgml
 1
and incubated on ice for 20min in the dark. Samples were analysed
by flow cytometry using an established method for assessment
of cell viability in transfected cells selected according to GFP
fluorescence (Vezina et al, 2001).
Tumour collection
The protocol was approved by the ethics (medical research)
committee of Beaumont Hospital, Dublin and all patients provided
written, informed consent. Colon cancer tissue and matched
normal colonic mucosa were obtained from patients at the time of
surgery and were immediately placed in RNAlater solution (Qiagen
GmbH). Total RNA was extracted from the tissue samples as
above.
Additional patients with newly diagnosed distal CRCs were
recruited under a separate protocol, approved by the Irish
Medicines Board and Beaumont Hospital Ethics Committee, for
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streatment for 5–7 days with the selective COX-2 inhibitor
rofecoxib at a dose of 25mg daily. Tumour was sampled endo-
scopically at day 0 and again on completion of therapy and was
placed in RNAlater. Compliance with drug therapy was monitored
by measurement of whole-blood monocyte COX-2 activity as
previously described (Panara et al, 1995).
Statistical analysis
Analysis of tumour/normal differences were performed using two-
tailed Student’s t-test. Differences in gene expression across time
points were analysed by ANOVA with Bonferroni multiple
comparisons test. Linear correlation was assessed using Pearson’s
test. t-Test, ANOVA and correlation statistics were performed
using In-Stat, version 3.0 (GraphPad Software, La Jolla, CA, USA).
RESULTS
COX-2 modulates susceptibility to apoptosis in HCA7
colon cancer cell line
We examined the regulation of apoptosis by COX-2 in a human
CRC cell line. HCA7 cells have previously been reported to express
high levels of COX-2 with abundant PGE2 generation (Sheng et al,
1997). Apoptosis was quantified by fluorescence labelling with
FITC-conjugated antibody to Annexin V and propidium iodide
assessed by flow cytometry (Figure 1). Following a 24h treatment
with the selective COX-2 inhibitor SC236 (5mM), a significant
decrease (P¼0.01) in HCA7 cells viability was observed
(Figure 1B), mirrored by a doubling of the proportion of the cell
population gated to the early apoptosis phase (Annexin V positive,
propidium iodide negative) (Figure 1B). The observed increase in
apoptosis at low micromolar doses of SC236 was prevented by co-
administration of exogenous PGE2 (1mM), whereas more marked
increases in apoptosis seen with higher doses of SC236 were not
rescued. A similar effect was noted with regard to effects on cell
proliferation (see Supplementary Figure S1). The ability of PGE2 to
promote cell survival confirmed that at low micromolar doses the
effects of SC236 are largely dependant on its ability to inhibit
COX-2.
High-density oligonucleotide arrays identify SC236-
mediated changes in gene expression in HCA7 cells
Having confirmed that COX-2 inhibition causes an apoptotic
phenotype in HCA7, we used high-density oligonucleotide micro-
arrays (HDONAs) to examine early global changes in gene
expression associated with the abolition of prostaglandin production.
Total RNA from cells treated with SC236 (5mM) or vehicle control for
4 ,6o r8 hw a sp o o l e da n du s e dt op r o b eA f f y m e t r i xH G U 9 5 A v 2
GeneChips that feature probe sets for over 12000 different human
transcripts. Three independent biological replicates were assayed for
each condition (i.e. vehicle control or COX-2 inhibitor).
Robust Multichip Average (RMA)-based analysis was performed
to compare expression measures. Magnitude of changes in
expression of individual genes was small in most cases, reflecting
the early time points used. Correspondence analysis (CoA) of
RMA-based measures, however, highlighted significant global
differences in gene expression between control and treated
samples (Figure 2A). This technique, similar to principal
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Figure 1 Regulation of HCA7 cell viability and apoptosis by COX-2 inhibition. (A) Representative examples of the distribution of staining for
FITC–Annexin V (x axis, FL1) and propidium iodide (y axis, FL3) in HCA7 cells treated for 24h with vehicle control (top), SC236 (5mM, middle) and SC236
(5mM)/PGE2 (1mM, bottom). (B) Quantification of cell viability and apoptosis. Viable cells (upper chart) and cells in early stages of apoptosis showing positive
Annexin V staining but negative for propidium iodide (lower chart), represented as a percentage of the total cell population. Values shown are mean
percentages±s.e.m. of total cell counts across replicate experiments (n¼4); *Po0.05, **Po0.01; one-way ANOVA. Each replicate involved the counting
of a total of a minimum of 10000 events.
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Figure 2 Microarray analysis identifies DRAK2 as one of a number of genes regulated by COX-2 inhibition. (A) HCA7 cells display a distinct expression
profile following treatment with SC236 (RX, pink) vs cells treated with vehicle control (Ctrl, red). The each of four panels illustrates different views of a
three-dimensional correspondence analysis (CoA) of RMA-derived expression measures. (B) DRAK2 gene expression in HCA7 cells on treatment with
control, SC236 (5mM) for 4 or 24h with and without co-treatment with PGE2(1mM). Results of qRT-PCR analysis are expressed as the ratio of DRAK2 to
18S rRNA. Values shown are the mean±s.e.m. across replicate experiments (n¼5). (P-values are for one-way ANOVA). (C) Confocal microscopy of
indirect immunofluorescent staining for DRAK2 (green) in HCA7 cells treated with vehicle control or SC236 (5mM) for 24h with propidium iodide as a
nuclear counterstain (red) (original magnification,  400).
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scomponents analysis, represents expression (hybridisation) as
points projected in three-dimensional space and demonstrates a
consistent alteration in the transcriptome of cells treated with
COX-2 inhibitor.
Expression of DRAK2 (STK17b) consistently showed strong
induction with COX-2 inhibition. This novel serine–threonine
kinase is a member of the death-associated protein (DAP) kinase
family and like other family members has been implicated in the
control of apoptosis (Sanjo et al, 1998). However, a potential
function in the regulation of cell death and viability in cancer has
not been explored to date. A comparison of our expression data set
with another recently published HDONA experiment (Levitt et al,
2004) (evaluating selective COX-2 inhibition in a breast cell line)
revealed a cluster of genes regulated by COX-2 in both systems (see
Supplementary data; Table S1) and differential expression of
DRAK2 once again featured as a strong signal. It was thus chosen
for detailed validation and further analysis.
Expression of DRAK2 in HCA7 cells is regulated by COX-2
and PGE2
Differential DRAK2 expression was confirmed by quantitative
RT-PCR (qRT-PCR) on template from HCA7 cells. Induction of
DRAK2 expression was observed as early as 4h after treatment
with SC236 and was inhibited by co-administration of PGE2
(Figure 2B). A 4.4-fold induction of DRAK2 expression (relative to
control) was observed with SC236 (5mM) after 4h (P¼0.001), a
response that was attenuated on co-incubation with prostaglandin
(SC236 vs SC236þPGE2, P¼0.01), suggesting that the changes in
DRAK2 expression were dependant on variations in prostaglandin
generation. Indirect immunofluorescent staining for DRAK2 in
HCA7 cells showed a corresponding increase in levels of DRAK2
protein with COX-2 inhibitor treatment, with development of
intense nuclear staining for DRAK2 at 24h post-treatment with
SC236 (Figure 2C).
Reduced DRAK2 expression in human colorectal tumours
We examined the expression of both DRAK2 and COX-2 in a bank
of colorectal tumour samples using total RNA extracted from
tumour and normal mucosa sampled from the freshly resected
tumours of 10 patients with CRC (not taking aspirin or NSAIDs).
The levels of COX-2 transcript (normalised to 18S rRNA) were
elevated in the majority of tumour samples relative to normal
mucosa (Figure 3B, mean 2.4-fold increase, P¼0.006). DRAK2
expression showed an opposite pattern, with relative suppression
of DRAK2 expression in tumour compared to normal from the
same patient (Figure 3A, mean decrease approximately 50%,
P¼0.003). A negative correlation between the ratio of DRAK2 and
COX-2 expression (in tumour relative to normal) was noted
(Figure 3C, R¼ 0.68, R
2¼0.46, P¼0.03) reflecting an inverse
relationship between the tumour/normal differences for the two
genes across the patients sampled.
DRAK2 expression in colorectal tumours is suppressed by
COX-2
Our observations suggested a suppression of DRAK2 expression,
either directly or indirectly, by the actions of COX-2-derived
prostaglandins in tumour samples. To test this hypothesis further,
five patients with newly diagnosed CRC (not taking aspirin or
NSAIDS) were recruited to a pilot study. Endoscopic biopsies
of tumour tissue were obtained before and after a short course
(5–7 days) of treatment with the COX-2-selective inhibitor
rofecoxib at a dose of 25mg daily, a dose that has been
demonstrated to selectively inhibit COX-2 in vivo (Ehrich et al,
1999). The study was conducted before the withdrawal of rofecoxib
by the manufacturer. qRT-PCR demonstrated an induction in
DRAK2 expression (Figure 4A; mean 2.5-fold increase, P¼0.01) in
tumour from each of the patients treated with rofecoxib, reflective
of the changes seen with COX-2 inhibition in vitro. The expression
of a panel of additional genes was also evaluated for comparative
purposes (Figure 4B). Although no significant change in several
genes that modulate apoptosis (Bax, Bcl-xl) was observed, a
significant decrease in VEGF expression was noted, with a mean
reduction of close to 40% (P¼0.01). This pro-angiogenic factor
has previously been linked to COX-2 activity and reduced VEGF
expression has been observed in animal models following
treatment with rofecoxib (Yao et al, 2003). This finding provided
additional validation of the suppression of COX-2 activity in the
tumours of these patients.
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Figure 3 Relationship between expression of DRAK2 and COX-2 in
colorectal cancer. (A) DRAK2 expression normalised to 18S (as measured
by qRT-PCR) in template extracted from normal colorectal mucosa and
from colorectal tumour with a line linking the tumour and normal value for
each patient (n¼10). The bar chart shows the mean level of expression in
normal and tumour overall (error bars indicate s.e.m., P-values for paired
Student’s t-test). (B) COX-2 expression normalised to 18S (as measured
by qRT-PCR) in the same patient group as above. (C) The ratio of COX-2
expression (y axis) and DRAK2 expression (x axis) in tumour relative to
normal for the purposes of linear correlation.
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COX-2 inhibition
Finally we evaluated the phenotypic activity of DRAK2 in cell
systems. We suspected DRAK2 expression was already signifi-
cantly suppressed in HCA7 cells, given high levels of COX-2
expression whereas HT-29 cells showed lower levels of COX-2 with
higher levels of DRAK2 expression. Following transient trans-
fection of HT-29 cells with a commercially available sequence
validated siRNA to DRAK2, significant repression of DRAK2
transcription was seen (Figure 5A). To counteract the effects of
low transfection efficiency and maximise detection of a phenotype
associated with DRAK2 silencing, a GFP expression vector was co-
transfected to ‘gate’-transfected or ‘silenced’ cells in subsequent
assays to quantify cell survival using an established method
(Vezina et al, 2001). The percentage of viable cells (without 7-ADD
uptake) and non-viable cells (with 7-ADD uptake) was calculated
in mock-transfected cells and in DRAK2 siRNA-transfected cells
selected (gated) by GFP fluorescence. Loss of cell viability was
observed in mock-transfected HT-29 cells following treatment
with both SC236 and staurosporine (Figure 5B). In contrast, the
siRNA-transfected (GFP-gated) cells showed no loss of cell
viability following treatment with the COX-2 inhibitor SC236.
They did however still show a significant loss of viability with
staurosporine, suggesting a specific effect on the pathway involved
in the action of SC236.
DISCUSSION
Traditional NSAIDs have anti-neoplastic properties, but their
prolonged use is limited by their association with gastrointestinal
side effects, particularly the risk of gastrointestinal haemorrhage.
The new-generation coxibs have also shown promise for chemo-
prevention of CRC but are now considered by many to carry an
unacceptable risk of thrombotic events. Our aim was to identify
novel ‘effector’ pathways operating downstream of COX-2 in
tumours, so that this knowledge might allow future selection of
more refined therapeutic targets.
There are a number of ways in which COX-2 may promote
cancer progression, either through an effect on cancer cells, the
associated immune response or angiogenesis in response to the
tumour. There is evidence that COX-2 expression protects cells
from apoptosis and conversely that treatment of CRC cells with
selective COX-2 inhibitors causes cell-cycle arrest, growth inhibi-
tion and induction of apoptosis (Richter et al, 2001; Sheng et al,
1997, 1998). Evidence from both animal models (Hansen-Petrik
et al, 2002) and human studies (Sinicrope et al, 2004) suggests that
modulation of cell survival by altered susceptibility to apoptosis is
equally important in vivo.
However, the precise mechanisms by which COX-2 exerts these
effects in tumour cells are unclear. Enhanced COX-2 expression in
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control cells. Cells transfected with DRAK2 siRNA were selected by co-
transfection of a GFP vector and cell viability was then assessed by uptake
of 7-aminoactinomycin D using an established method (Vezina et al, 2001).
Mean values±s.e.m. (n¼3); *Po0.05, **Po0.01, one-way ANOVA.
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scells alters susceptibility to tumour necrosis factor-related
apoptosis-inducing ligand by reduction in membrane death
receptors (Tang et al, 2002) and may also alter the threshold for
intrinsic pathway activation (Tang et al, 2002). Over-expression of
COX-2 leads to the generation of prostanoids, particularly PGE2,
and signalling through the various EP receptors, several of
which have been implicated in carcinogenesis (Watanabe et al,
1999; Sonoshita et al, 2001; Mutoh et al, 2002). PGE2 stimulates
TCF-b-catenin-mediated gene transcription (Castellone et al,
2005; Shao et al, 2005; Eisinger et al, 2007), possibly by activation
of EP2 and EP4 receptors (Fujino et al, 2002). Some of
the important effects of PGE2 are probably also related to its
ability to transactivate the epidermal growth factor receptor
through a number of distinct mechanisms (Pai et al, 2002; Shao
et al, 2003; Al-Salihi et al, 2007). It seems likely therefore that
prostaglandins generated by CRC cells do not exert their activity
by a single mechanism but have a range of downstream signalling
targets.
We made use of HDONAs to identify ‘early’ target genes
downstream of COX-2. Earlier studies in other cell systems have
demonstrated the ability of COX-2 to regulate gene expression,
such as the expression of MDR1 (Patel et al, 2002). Specific studies
of differential gene expression in colon cancer cells (using
suppressive subtractive hybridisation and differential screening)
have previously demonstrated altered expression of genes involved
in cell proliferation and viability (Zhang and DuBois, 2001),
however high NSAID doses and long time points make a direct
comparison with our expression studies difficult. We chose to look
at early time points following treatment with the highly selective
COX-2 inhibitor SC236 to identify crucial early responses. COX-2
independent effects of SC236 have been described (He et al, 2006).
However, we chose to use SC236 at a dose which was associated
with only modest changes in rates of apoptosis but where we
observed rescue by co-incubation with PGE2, in the belief that
study of a more subtle but specific phenotypic change would yield
more significant findings.
We identified DRAK2 as showing consistent changes in
expression. This predominantly nuclear serine–threonine kinase
has similarity to the DAP kinases and is involved (at least in
certain cell types) in initiation of apoptosis (Sanjo et al, 1998).
Unsupervised hierarchical clustering of our expression data
(Supplementary Figure S2) selected a cluster of genes showing a
similar pattern of upregulation with COX-2 inhibition. This cluster
of genes have either known nuclear localisation within the cell or
have a bipartite nuclear localisation signal, which suggests their
ability to traffic to the nucleus. Many of these are known to be
involved in transcriptional regulation or in the induction or
potentiation of apoptosis. Prior expression analyses have pre-
viously identified nuclear proteins as significantly over-repre-
sented in genes induced by aspirin treatment in colon cancer cells
(Hardwick et al, 2004) and a mechanism regulating the nuclear
trafficking of DRAK2 has recently been suggested (Kuwahara
et al, 2008).
We have confirmed that DRAK2 expression in colon cancer cells
in vitro is regulated by COX-2 (Figure 2) and also demonstrated an
in vivo relationship between COX-2 and DRAK2 expression in
human CRC (Figure 3). Both COX-2 and DRAK2 have been
implicated in the modulation of T-lymphocyte function, with
opposing phenotypic consequences. Activated T cells in patients
with SLE markedly upregulate and sustain COX-2 expression and
resist inactivation and cell death (Xu et al, 2004). Indeed, COX-2
expression has been shown to mediate lethal T-cell activation
(Brewer et al, 2003). By contrast, over-expression of DRAK2 in
activated T cells enhances apoptosis in the presence of IL-2 (Mao
et al, 2006), and studies in mice with targeted disruption of DRAK2
have demonstrated that this protein is an important negative
regulator of T-cell activation, raising the threshold for activa-
tion through the T-cell receptor (McGargill et al, 2004; Friedrich
et al, 2005) and acting as an important regulator of T cells response
and survival (Schaumburg et al, 2007; McGargill et al, 2008).
Although it is clear that DRAK2-mediated cell death is cell-type
and context dependent, there is a growing body of evidence to
indicate that its function is directly related to the regulation of cell
survival. In addition to in vivo evidence from DRAK2 transgenic
mice (Mao et al, 2006), induction of DRAK2 in vitro in a variety
of contexts and cell types augments apoptosis (Sanjo et al, 1998;
Kuwahara et al, 2006; Mao et al, 2006). We also show that silencing
DRAK2 expression in HT29 cells promotes cell survival and
abrogates the effects of a COX-2 inhibitor in vitro. These findings
confirm published observations on the effect of DRAK2 silencing
by RNAi on susceptibility of rat colon cancer cells to UV-induced
apoptosis (Kuwahara et al, 2006). We also recently observed that
DRAK2 may be important in the ability of COX-2 to protect
cardiomyocytes from doxorubicin-induced apoptosis (Neilan et al,
2006), suggesting that the modulation of DRAK2 expression may
not be confined to cancer but may also be important in the positive
effects of COX-2 on cell viability and tissue healing in other
systems. For the moment, the precise mechanisms by which
DRAK2 impacts on cell survival are unclear. Recent observations
suggest that the ribosomal kinase p70S6, involved in cell-cycle
regulation, is a substrate for DRAK2 (Mao et al, 2009), highlighting
a possible involvement in regulation of cell-cycle dynamics. In an
analysis of publicly available expression data (Whitfield et al,
2002), we have noted that DRAK2 forms part of a cluster of genes
showing similar cyclical changes in expression with cell-cycle
periodicity in HeLa cells (Supplementary Figure S3; Supplemen-
tary Table 2). There is an interesting degree of overlap
(summarised concisely in Supplementary Figure 4) between this
panel and COX-2-regulated genes identified by our gene expres-
sion analysis and a number of other gene discovery studies that
examined the effects of COX inhibitors (Iizaka et al, 2002; Levitt
et al, 2004).
How does the identification of the regulation of DRAK2 by
COX-2 further our understanding of the role of COX-2 in cancer?
One of the most consistent observations about COX-2 in cancer is
its contribution in vivo to the risk of systemic metastases
(Tomozawa et al, 2000; Yao et al, 2004). This fact likely explains
the impaired survival observed in individuals whose tumours
express COX-2 (Sheehan et al, 1999). Previous observations about
the effects of DAP kinase (the best-characterised member of the
kinase family to which DRAK2 belongs) in cancer cells may
provide a unifying explanation, linking the ability of this DAP
kinase to regulate apoptosis to a suppression of metastatic
potential (Inbal et al, 1997). The most plausible explanation
is that the enhanced cell survival conferred by DRAK2 silencing
(by COX-2) provide a resistance to various forms of cell death
and possibly crucially to anoikis (matrix detachment-induced cell
death) (Hofmann et al, 2007), the form of cell death that may be
the most important in deciding the viability of circulating tumour
cells and their ability to form distant metastases.
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